Zydus Lifesciences Ltd
ZYDUSLIFE • Health Care
ROCE
25.54%
FY24 Actual
D/E Ratio
0.12
Leveraged
5Y Rev CAGR
12.8%
High Growth
Profit Margin
| Metrics (Values in Cr) | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | TTM |
|---|---|---|---|---|---|---|
| Total Revenue | 17,848.3 | 17,424(-2.4%) |
ZYDUSLIFE • Health Care
ROCE
25.54%
FY24 Actual
D/E Ratio
0.12
Leveraged
5Y Rev CAGR
12.8%
High Growth
Profit Margin
| Metrics (Values in Cr) | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | TTM |
|---|---|---|---|---|---|---|
| Total Revenue | 17,848.3 | 17,424(-2.4%) |
18.7%
5Y Average
23,511(+18.4%) |
27,657.9(+17.6%) |
27,657.9 |
| Operating Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Operating Profit | — | — | — | — | — | — |
| Raw Profit | 5,907.5 | 6,072(+2.8%) | 6,478.4(+6.7%) | 6,522.9(+0.7%) | — | — |
| Operating Expenses | 1,057.3 | 2,089.2(+97.6%) | 1,333.3(-36.2%) | 1,991.3(+49.4%) | 19,189.9(+863.7%) | 19,189.9 |
| Selling General And Administrative Expenses | 2,210.6 | 2,697.9(+22.0%) | 2,846.7(+5.5%) | 3,832.4(+34.6%) | — | — |
| Depreciation And Amortization | 713 | 722.7(+1.4%) | 764.1(+5.7%) | 915.8(+19.9%) | 1,408(+53.7%) | 1,408 |
| Profit Before Interest | 5,210.8 | 2,715(-47.9%) | 4,913.1(+81.0%) | 6,192.6(+26.0%) | 7,060(+14.0%) | 7,060 |
| Interest Expense | 127 | 129.9(+2.3%) | 81.2(-37.5%) | 165.9(+104.3%) | 438.9(+164.6%) | 438.9 |
| Profit Before Tax | 5,083.8 | 2,585.1(-49.2%) | 4,831.9(+86.9%) | 6,026.7(+24.7%) | 6,621.1(+9.9%) | 6,621.1 |
| Tax Expense | 596.5 | 624.8(+4.7%) | 972.4(+55.6%) | 1,501.2(+54.4%) | 1,581.1(+5.3%) | 1,581.1 |
| Net Income | 4,487.3 | 1,960.3(-56.3%) | 3,859.5(+96.9%) | 4,525.5(+17.3%) | 5,040(+11.4%) | 5,040 |
| Earnings Per Share | 43.832 | 19.257(-56.1%) | 38.242(+98.6%) | 44.975(+17.6%) | 50.09(+11.4%) | 50.088 |
| Dividends Per Share | 2.5 | 6(+140.0%) | 3(-50.0%) | 11(+266.7%) | 1(-90.9%) | 11 |
| Payout Ratio | 0.057 | 0.312(+446.3%) | 0.078(-74.8%) | 0.245(+211.8%) | 0.02(-91.8%) | 0.22 |